Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma

home / oncclub / infigratinib-represents-new-option-for-fgfr2-cholangiocarcinoma

Sameek Roychowdhury, MD, PhD, contextualizes safety and efficacy data reported from a phase 2 study (NCT02150967) examining infigratinib (Truseltiq) in patients with FGFR2-positive cholangiocarcinoma, describes nuances to treatment with the agent, and sheds light on ongoing research efforts being made to further improve outcomes in this population.